Canada questions safety of Nexium, Prilosec

Health Canada says it's reviewing new safety data on AstraZeneca's heartburn drugs Nexium and Prilosec. The preliminary data shows patients may have had more heart attacks and other cardiac problems than did patients who treated their digestive problems with surgery. The FDA, however, says its review of the data found no increased risk of heart problems. Nexium is AstraZeneca's best-selling drug, with worldwide sales of $1.3 billion during the second quarter of 2007.

- check out this article

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.